Galidesivir limits Rift Valley fever virus infection and disease in Syrian golden hamsters

Antiviral Research

Volumn 156, Issue , 2018, Pages 38-45

  Westover, Jonna B ^a   Mathis, Amanda ^b   Taylor, Ray ^b   Wandersee, Luci ^a   Bailey, Kevin W ^a   Sefing, Eric J ^a   Hickerson, Brady T ^a   Jung, Kie Hoon ^a   Sheridan, William P ^b   Gowen, Brian B ^a  

^a UTAH STATE UNIVERSITY   (United States)

^b BIOCRYST PHARMACEUTICALS INC   (United States)

Author keywords

BCX4430; Bunyavirus; Galidesivir; Phlebovirus; Rift valley fever virus; Viral hemorrhagic fever

Indexed keywords

GALIDESIVIR; RIBAVIRIN; 2-(4-AMINO-5H-PYRROLO(3,2-D)PYRIMIDIN-7-YL)-5-(HYDROXYMETHYL)PYRROLIDINE-3,4-DIOL; ANTIVIRUS AGENT; PURINE NUCLEOSIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BRAIN; CC50; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG EXCRETION; DRUG POTENCY; DRUG TOLERABILITY; EC50; EC90; FEMALE; LIVER; LOADING DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MORBIDITY; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SERUM; SINGLE DRUG DOSE; SPLEEN; SURVIVAL RATE; SYRIAN HAMSTER; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME; VIRUS INHIBITION; VIRUS STRAIN; VIRUS TITRATION; VOLUME OF DISTRIBUTION; ANIMAL; DISEASE MODEL; DRUG EFFECT; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; MESOCRICETUS; SURVIVAL ANALYSIS; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; LIVER; MESOCRICETUS; PURINE NUCLEOSIDES; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SPLEEN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 85048187896     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2018.05.013     Document Type: Article

References (19)

1. Bird, B.H., Ksiazek, T.G., Nichol, S.T., Maclachlan, N.J., Rift Valley fever virus. J. Am. Vet. Med. Assoc. 234 (2009), 883–893.
2. Eyer, L., Zouharová D., Širmarová J., Fojtíková M., Štefánik, M., Haviernik, J., Nencka, R., de Clercq, E., Růžek, D., Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses. Antivir. Res. 142 (2017), 63–67.
3. Golnar, A.J., Kading, R.C., Hamer, G.L., Quantifying the potential pathways and locations of Rift Valley fever virus entry into the United States. Trans. Emerg. Dis. 65 (2017), 85–95.
4. Gowen, B.B., Wong, M.H., Jung, K.H., Sanders, A.B., Mendenhall, M., Bailey, K.W., Furuta, Y., Sidwell, R.W., In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51 (2007), 3168–3176.
5. Hartman, A.L., Powell, D.S., Bethel, L.M., Caroline, A.L., Schmid, R.J., Oury, T., Reed, D.S., Aerosolized rift valley fever virus causes fatal encephalitis in african green monkeys and common marmosets. J. Virol. 88 (2013), 2235–2245.
6. Ikegami, T., Makino, S., The pathogenesis of Rift Valley fever. Viruses 3 (2011), 493–519.
7. Julander, J.G., Bantia, S., Taubenheim, B.R., Minning, D.M., Kotian, P., Morrey, J.D., Smee, D.F., Sheridan, W.P., Babu, Y.S., BCX4430, a novel nucleoside analog, effectively treats yellow fever in a Hamster model. Antimicrob. Agents Chemother. 58 (2014), 6607–6614.
8. Julander, J.G., Siddharthan, V., Evans, J., Taylor, R., Tolbert, K., Apuli, C., Stewart, J., Collins, P., Gebre, M., Neilson, S., Van Wettere, A., Lee, Y.M., Sheridan, W.P., Morrey, J.D., Babu, Y.S., Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model. Antivir. Res. 137 (2017), 14–22.
9. Kortekaas, J., One Health approach to Rift Valley fever vaccine development. Antivir. Res. 106 (2014), 24–32.
10. McElroy, A.K., Nichol, S.T., Rift Valley fever virus inhibits a pro-inflammatory response in experimentally infected human monocyte derived macrophages and a pro-inflammatory cytokine response may be associated with patient survival during natural infection. Virology 422 (2012), 6–12.
11. NIAID, NIAID Emerging Infectious Diseases/Pathogens. 2016, National Institute of Allergy and Infectious Diseases https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens.
12. Reed, L.J., Muench, H., A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27 (1938), 493–497.
13. Scharton, D., Bailey, K.W., Vest, Z., Westover, J.B., Kumaki, Y., Van Wettere, A., Furuta, Y., Gowen, B.B., Favipiravir (T-705) protects against peracute Rift Valley fever virus infection and reduces delayed-onset neurologic disease observed with ribavirin treatment. Antivir. Res. 104 (2014), 84–92.
14. Scharton, D., Van Wettere, A.J., Bailey, K.W., Vest, Z., Westover, J.B., Siddharthan, V., Gowen, B.B., Rift Valley fever virus infection in golden Syrian hamsters. PLoS One, 10, 2015, e0116722.
15. Smith, D.R., Bird, B.H., Lewis, B., Johnston, S.C., McCarthy, S., Keeney, A., Botto, M., Donnelly, G., Shamblin, J., Albariño, C.G., Nichol, S.T., Hensley, L.E., Development of a novel nonhuman primate model for Rift Valley fever. J. Virol. 86 (2012), 2109–2120.
16. Taylor, R., Kotian, P., Warren, T., Panchal, R., Bavari, S., Julander, J., Dobo, S., Rose, A., El-Kattan, Y., Taubenheim, B., Babu, Y., Sheridan, W.P., BCX4430 - a broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease. J. Inf. Public Health 9 (2016), 220–226.
17. Turell, M.J., Dohm, D.J., Mores, C.N., Terracina, L., Wallette, D.L.J., Hribar, L.J., Pecor, J.E., Blow, J.A., Potential for North American mosquitoes to transmit Rift Valley fever virus. J. Am. Mosq. Contr. Assoc. 24 (2008), 502–507.
18. Warren, T.K., Wells, J., Panchal, R.G., Stuthman, K.S., Garza, N.L., Van Tongeren, S.A., Dong, L., Retterer, C.J., Eaton, B.P., Pegoraro, G., Honnold, S., Bantia, S., Kotian, P., Chen, X., Taubenheim, B.R., Welch, L.S., Minning, D.M., Babu, Y.S., Sheridan, W.P., Bavari, S., Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430. Nature 508 (2014), 402–405.
19. WHO, 2018 annual Review of the Blueprint List of Priority Diseases. 2018, World Health Organization http://www.who.int/blueprint/priority-diseases/en/.